Treatment for Non-Hodgkin's Lymphoma (NHL)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Stanford Cancer Center, San Francisco, CA
Non-Hodgkin's Lymphoma (NHL)+1 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test if a new cancer treatment improves the thinking skills of patients. This treatment is used to treat Non-Hodgkin's Lymphoma (NHL). Since there is no placebo involved, all patients in this trial will receive the treatment. The treatment can be done online.

Eligible Conditions

  • Non-Hodgkin's Lymphoma (NHL)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Non-Hodgkin's Lymphoma (NHL)

Study Objectives

2 Primary · 9 Secondary · Reporting Duration: 6 months

6 months
Number of patients who complete neuropsychological testing in the post-CAR-T adult population
Number of patients who complete telehealth neuropsychological testing in the post-CAR-T adult
Baseline
Clock Drawing Test
Controlled Oral Work Association Test COWAT
Digit Span
General Anxiety Disorder Assessment GAD-7
Hopkins Verbal Learning Test HVLT
Patient Health Questionnaire PHQ9
Short form of Quality of Life SF-36
Trails A and B (Oral Trails)
Wechsler Test of Adult Reading WTAR Neuropsychological testing

Trial Safety

Safety Progress

1 of 3

Other trials for Non-Hodgkin's Lymphoma (NHL)

Trial Design

0 Treatment Group

20 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
Closest Location: Stanford Cancer Center · San Francisco, CA
Photo of San Francisco 1Photo of San Francisco 2Photo of San Francisco 3
2012First Recorded Clinical Trial
8 TrialsResearching Non-Hodgkin's Lymphoma (NHL)
114 CompletedClinical Trials

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,132 Previous Clinical Trials
35,669,096 Total Patients Enrolled
14 Trials studying Non-Hodgkin's Lymphoma (NHL)
2,904 Patients Enrolled for Non-Hodgkin's Lymphoma (NHL)
Brian Scott, MDPrincipal InvestigatorStanford University

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are at least 18 years old.
You are treated with Axicabtagene ciloleucel CAR-T therapy at Stanford University.
You are aged >/= 6 months from the date of CAR-T infusion.
You are fluent in English.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.